Showing 1971-1980 of 2165 results for "".
- Glaukos Submits Supplemental Pre-Market Approval Application for iStent Infinitehttps://modernod.com/news/glaukos-submits-supplemental-pre-market-approval-application-for-istent-infinite/2479482/Glaukos announced that it has submitted a supplemental pre-market approval (PMA) application to the FDA for the iStent infinite Trabecular Micro-Bypass System. The iStent infinite is an investigational device designed for use in a standalone procedure to reduce elevated IOP in p
- Holland Foundation for Sight Restoration Launched to Provide Life Changing Eye Surgerieshttps://modernod.com/news/holland-foundation-for-sight-restoration-launched-to-provide-life-changing-eye-surgeries/2479402/Edward Holland, MD, a pioneering ophthalmologist in the treatment of Severe Ocular Surface Disease, today announced the launch of the Holland Foundation for Site Restoration with a goal of establishing Centers of Excellence (COEs) throughout the country that would specialize in site restoration p
- Pfizer, BioNTech’s COVID-19 Vaccine Neutralizes Brazil Variant in Lab Studyhttps://modernod.com/news/pfizer-biontechs-covid-19-vaccine-neutralizes-brazil-variant-in-lab-study/2478953/According to laboratory study findings published Monday in the NEJM, Pfizer and BioNTech’s mRNA-based COVID-19 vaccine BNT162b2 was able to neutralize the P.1 variant of SARS-CoV-2 that first surfaced in Brazil. The news follows a report late last week that suggested AstraZeneca’s cor
- Nicox Initiates Second Phase 3 Trial of NCX 470 in Glaucomahttps://modernod.com/news/nicox-initiates-second-phase-3-trial-of-ncx-470-in-glaucoma/2478515/Nicox announced the initiation of the second phase 3 clinical trial of NCX 470 (Denali) evaluating NCX 470 for the lowering of IOP in patients with open-angle glaucoma or ocular hypertension. The first patients were enrolled in the U.S. on November 9, 2020. NCX 470, Nicox’s lead clinical p
- AAO Data: Experimental RNA Based Drug Addresses the Underlying Cause of Rare Eye Diseasehttps://modernod.com/news/aao-data-experimental-rna-based-drug-addresses-the-underlying-cause-of-rare-eye-disease/2478509/At the virtual AAO 2020 meeting, ProQR Therapeutics will present two posters on its lead product candidate sepofarsen for the treatment of the root cause of Leber congenital amaurosis 10 (LCA10), a rare eye disease that damages the development of the retina and causes severe vision loss. P
- Sun Ophthalmics to Present E-Posters at AAOpthttps://modernod.com/news/sun-ophthalmics-to-present-e-posters-at-aaopt/2478370/Sun Ophthalmics announced that is will be present several e-posters at the upcoming virtual AAOpt meeting being held this week. Author Presentation October 7, 4-6 pm, Session: Anterior Segment I Toyos M, Shen Lee B, Schechter B, Ogundele A, Gupta P, K
- AGTC Announces Updated Development Plan for its X-Linked Retinitis Pigmentosa Clinical Programhttps://modernod.com/news/agtc-announces-updated-development-plan-for-its-x-linked-retinitis-pigmentosa-clinical-program/2478058/Applied Genetic Technologies Corporation announced next steps in the clinical development of the company’s potential treatment of X-linked retinitis pigmentosa (XLRP) caused by mutations in the RPGR gene following receipt of written feedback from the FDA. The revised development p
- NIAID Launches ACTT 2 Trial Testing Gilead’s Remdesivir Plus Eli Lilly, Incyte’s JAK Inhibitor Olumiant in COVID-19https://modernod.com/news/niaid-launches-actt-2-trial-testing-gileads-remdesivir-plus-eli-lilly-incytes-jak-inhibitor-olumiant-in-covid-19/2477741/The US National Institute of Allergy and Infectious Diseases (NIAID) said Friday that it is enrolling hospitalized adults with COVID-19 in the US to take part in a study evaluating the combination of Gilead Sciences’ remdesivir with Eli Lilly and Incyte’s JAK inhibitor Olumiant as a p
- SightGlass Vision Unveils Topline Data From Study of Novel Eyeglasses Designed to Control Myopia in Childrenhttps://modernod.com/news/sightglass-vision-unveils-topline-data-from-study-of-novel-eyeglasses-designed-to-control-myopia-in-children/2477653/SightGlass Vision announced topline data from the company’s pivotal trial evaluating its novel eyeglasses designed to slow the progression of myopia in children. Results from a planned 12-month interim analysis of the CYPRESS clinical study (NCT03623074) demonstrated a reduction in myopia p
- Tatsuya Kaihara Appointed CEO of Santen Inc. and Head of North America Business of Santen Pharmaceuticalhttps://modernod.com/news/tatsuya-kaihara-appointed-ceo-of-santen-inc-and-head-of-north-america-business-of-santen-pharmaceutical/2477510/Santen announced the appointment of Tatsuya Kaihara as Corporate Officer and Head of North America Business of Santen Pharmaceutical. As of April 1, he is also appointed as CEO of Santen Inc. and he will lead the company’s North America business and report to Shigeo Taniuchi, P